Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.38 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | FBP1 | P09467 | 2/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955091 | 1.00 | XDH (0.42) | XDHCYP19A1TSHRERN1NFE2L2 | |
| SCHEMBL348330 | 0.85 | CYP19A1 (0.56) | XDHCYP19A1TSHRERN1NFE2L2 | |
| SCHEMBL1548019 | 0.85 | CYP19A1 (0.50) | XDHCYP19A1TSHRERN1NFE2L2 | |
| SCHEMBL24934311 | 0.82 | CYP19A1 (0.40) | CYP19A1TSHRNFE2L2VCAM1ALDH1A1 | |
| SCHEMBL16951590 | 0.82 | CYP19A1 (0.40) | CYP19A1TSHRNFE2L2ALDH1A1HIF1A | |
| SCHEMBL30508453 | 0.81 | HSPB1 (0.44) | XDHERN1ALDH1A1 | |
| SCHEMBL25409075 | 0.81 | HSPB1 (0.44) | XDHERN1ALDH1A1 | |
| SCHEMBL7203812 | 0.80 | CYP19A1 (0.62) | CYP19A1TSHRVCAM1ALDH1A1HIF1A | |
| SCHEMBL1172437 | 0.80 | CYP19A1 (0.55) | CYP19A1TSHRVCAM1ALDH1A1HIF1A | |
| Fluoride SCHEMBL27574861 | 0.78 | CYP19A1 (0.59) | CYP19A1TSHRVCAM1ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149881-B | Chiral derivatization reagent and preparation method and application thereof | 宁波大学 | 2022-07-19 | — | — | CN | claimed |
| CN-112679361-B | Synthetic method of 3-fluoro-5-nitropyridine-2-formaldehyde | 阿里生物新材料（常州）有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-113149881-A | Chiral derivatization reagent and preparation method and application thereof | 宁波大学 | 2021-07-23 | — | — | CN | claimed |
| CN-112679361-A | Synthetic method of 3-fluoro-5-nitrobenzaldehyde | 阿里生物新材料（常州）有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-118515616-B | Preparation method and application of squaraine small molecule compound and derivative | 华中农业大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-117720469-B | Preparation method and application of asymmetric urea micromolecule compound and derivative | 西南大学 | 2024-11-19 | — | — | CN | disclosed |
| CN-118515617-A | Preparation method and application of thiourea small molecular compound and derivative | 华中农业大学 | 2024-08-20 | — | — | CN | disclosed |
| CN-118515616-A | Preparation method and application of squaraine small molecule compound and derivative | 华中农业大学 | 2024-08-20 | — | — | CN | disclosed |
| WO-2024125629-A1 | UREIC COMPOUND AND PHARMACEUTICAL USE THEREOF AS STING INHIBITOR | 中国药科大学 | 2024-06-20 | — | — | WO | disclosed |
| CN-117756698-A | Urea compound and medical application thereof as STING inhibitor | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117720469-A | Preparation method and application of asymmetric urea micromolecule compound and derivative | 西南大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-113149881-B | Chiral derivatization reagent and preparation method and application thereof | 宁波大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20070197497-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007078839-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-20070161617-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
| WO-2007075377-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007070626-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070683-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006009726-A2 | SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES | CYTOKINETICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161617-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | XDH 274/4885CYP19A1 4882/4885TSHR 3989/4885 |
| US-20070197497-A1 | Compounds, compositions and methods | TNNI3, TNNC1, TNNT2 | XDH 369/4885CYP19A1 4883/4885TSHR 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.